Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Chairman and CEO Bruce Cozadd will deliver a corporate presentation and business update on January 14, 2025, at 9:45 a.m. PST.

The presentation will be accessible via webcast through the Investors section of Jazz Pharmaceuticals' website, with a replay available for 30 days post-conference. Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for serious diseases, particularly in sleep disorders, epilepsy, and cancer treatments. The company maintains its headquarters in Dublin, Ireland, with research, development, and manufacturing facilities across multiple countries.

DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43^rd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business update on Tuesday, January 14, 2025, at 9:45 a.m. PST / 5:45 p.m. GMT.

A live audio webcast of the presentation may be accessed via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be available on the website for 30 days following the conference.  

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com     
Ireland, +353 1 634 3211
U.S., +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland, +353 1 637 2141
U.S., +1 215 867 4948

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302334228.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When is Jazz Pharmaceuticals (JAZZ) presenting at the J.P. Morgan Healthcare Conference 2025?

Jazz Pharmaceuticals will present on Tuesday, January 14, 2025, at 9:45 a.m. PST / 5:45 p.m. GMT.

How can investors access JAZZ's J.P. Morgan Healthcare Conference presentation?

Investors can access the live audio webcast through the Investors section of Jazz Pharmaceuticals' website at investor.jazzpharma.com/investors/events-presentations. A replay will be available for 30 days following the conference.

What are the main therapeutic areas for Jazz Pharmaceuticals (JAZZ)?

Jazz Pharmaceuticals focuses on sleep disorders, epilepsy, and cancer treatments, with a growing portfolio of innovative therapeutics in oncology and neuroscience.

Where is Jazz Pharmaceuticals (JAZZ) headquartered?

Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with research and development laboratories and manufacturing facilities across multiple countries.

Who will be presenting for Jazz Pharmaceuticals (JAZZ) at the J.P. Morgan Healthcare Conference?

Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals, will provide the company overview and business update at the conference.